Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Figure 3
Ectopic MUC5AC expression is often positive in the cytoplasm of the mucous cells of the intestine in active CD (a, b, and d). Loss of MUC5AC expression is produced by adalimumab (ADA) in patients with remission stage (c). (a) ×100; (b) and (c) ×400; (d) ×40. Deep longitudinal ulceration was detected in the ileum by double balloon endoscopy (DBE) before ADA therapy (e) and the lesion showed mucosal healing after ADA therapy (f).
